141 related articles for article (PubMed ID: 7044523)
21. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
22. Aminoglutethimide in tamoxifen-resistant patients: The Melbourne Experience.
Murray RM; Pitt P
Cancer Res; 1982 Aug; 42(8 Suppl):3437s-3441s. PubMed ID: 6211229
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors affecting response to aminoglutethimide in advanced breast cancer.
Brufman G
Anticancer Res; 1993; 13(4):1235-7. PubMed ID: 8352549
[TBL] [Abstract][Full Text] [Related]
24. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
25. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
Ingle JN; Green SJ; Ahmann DL; Long HJ; Edmonson JH; Rubin J; Chang MN; Creagan ET
J Clin Oncol; 1986 Jun; 4(6):958-64. PubMed ID: 3519885
[TBL] [Abstract][Full Text] [Related]
27. Aminoglutethimide as second line endocrine therapy in advanced breast cancer.
Brufman G; Biran S
Anticancer Res; 1986; 6(5):1065-8. PubMed ID: 3800315
[TBL] [Abstract][Full Text] [Related]
28. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
[TBL] [Abstract][Full Text] [Related]
29. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
[TBL] [Abstract][Full Text] [Related]
30. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
[TBL] [Abstract][Full Text] [Related]
31. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA].
Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S
Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496
[TBL] [Abstract][Full Text] [Related]
32. [Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].
Zhang J; Zhang JH; Liu Y; Hao XM; Fang ZX; Li SL
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(46):3268-71. PubMed ID: 18396622
[TBL] [Abstract][Full Text] [Related]
33. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
34. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
Nomura Y; Tsutsui S; Murakami S; Takenaka Y
Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
[TBL] [Abstract][Full Text] [Related]
35. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
36. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
37. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
Harvey HA; Lipton A; White DS; Santen RJ; Boucher AE; Shafik AS; Dixon RJ
Cancer Res; 1982 Aug; 42(8 Suppl):3451s-3453s. PubMed ID: 6177405
[TBL] [Abstract][Full Text] [Related]
38. [Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast].
Bonneterre J; Pion JM; Demaille A
Bull Cancer; 1987; 74(3):241-7. PubMed ID: 3304478
[TBL] [Abstract][Full Text] [Related]
39. [Chemical adrenalectomy induced by aminoglutethimide in the treatment of breast cancer. A review].
Cikes M
Schweiz Med Wochenschr; 1983 Mar; 113(11):382-91. PubMed ID: 6342129
[TBL] [Abstract][Full Text] [Related]
40. [Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day].
Bonneterre J; Coppens H; Mauriac L; Rouesse J; Fargeot P; Metz R; Armand JP; Mathieu A; Tubiana M; Cappelaere P
Acta Clin Belg Suppl; 1986; 11():41-8. PubMed ID: 3521171
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
